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Myeloproliferative neoplasms (MPNs) are a group of diseases 
characterized by increased proliferation of erythroid, mega-
karyocytic, and granulocytic lineages. Three clinical entities 
designated polycythemia vera (PV), essential thrombocythe-
mia (ET), and primary myelofibrosis (MF [PMF]) are dis-
tinguished by clinical, laboratory, and molecular parameters 
(Tefferi et al., 2009). JAK2-V617F is the most frequently ob-
served somatic mutation in MPN. This mutation augments 
the tyrosine kinase activity of Jak2 and is found in >95% of 
patients with PV and in 50–60% of ET and PMF (Baxter et 
al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 
2005). Other driver mutations are primarily associated with 
ET and PMF and target the genes for calreticulin, CALR 
(Klampfl et al., 2013; Nangalia et al., 2013), and the throm-
bopoietin receptor, MPL (Pardanani et al., 2006; Pikman et 
al., 2006). Mutations in JAK2, CALR, and MPL are consid-
ered phenotypic driver mutations because they reproduce 
MPN phenotypes upon expression in mouse models. Genes 
encoding epigenetic regulators are also frequently mutated 
in MPN (Vainchenker et al., 2011). These mutations often 
coexist with one of the three driver gene mutations and are 
thought to promote clonal evolution and disease progression 
(Lundberg et al., 2014a). Mutations in the histone methyl-
transferase EZH2 (enhancer of zeste homologue 2) are de-
tected in 5–10% of patients with ET and PMF (Ernst et al., 
2010) but are also found in other hematologic malignancies, 
including myelodysplastic syndromes and acute myeloid leu-
kemia (Bejar et al., 2011; Gerstung et al., 2015). Patients with 
MPN carry either heterozygous or homozygous EZH2 mu-
tations (Ernst et al., 2010). Most of the EZH2 mutations in 
MPN result in truncations of the Ezh2 protein and are there-
fore predicted to be loss of function mutations. In patients 
with MF, EZH2 mutations are associated with poor prognosis 
(Guglielmelli et al., 2011).
Myeloproliferative neoplasm (MPN) patients frequently show co-occurrence of JAK2-V617F and mutations in epigenetic 
regulator genes, including EZH2. In this study, we show that JAK2-V617F and loss of Ezh2 in hematopoietic cells contribute 
synergistically to the development of MPN. The MPN phenotype induced by JAK2-V617F was accentuated in JAK2-
V617F;Ezh2−/− mice, resulting in very high platelet and neutrophil counts, more advanced myelofibrosis, and reduced survival. 
These mice also displayed expansion of the stem cell and progenitor cell compartments and a shift of differentiation toward 
megakaryopoiesis at the expense of erythropoiesis. Single cell limiting dilution transplantation with bone marrow from JAK2-
V617F;Ezh2+/− mice showed increased reconstitution and MPN disease initiation potential compared with JAK2-V617F alone. 
RNA sequencing in Ezh2-deficient hematopoietic stem cells (HSCs) and megakaryocytic erythroid progenitors identified highly 
up-regulated genes, including Lin28b and Hmga2, and chromatin immunoprecipitation (ChIP)–quantitative PCR (qPCR) anal-
ysis of their promoters revealed decreased H3K27me3 deposition. Forced expression of Hmga2 resulted in increased chimerism 
and platelet counts in recipients of retrovirally transduced HSCs. JAK2-V617F–expressing mice treated with an Ezh2 inhibitor 
showed higher platelet counts than vehicle controls. Our data support the proposed tumor suppressor function of EZH2 in 
patients with MPN and call for caution when considering using Ezh2 inhibitors in MPN.
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Several MPN mouse models have been established by 
expressing JAK2-V617F as transgenes or knock-in alleles (re-
viewed in Li et al. [2011]). Here we examined the effects of 
an Ezh2 loss of function mutation in a Cre-recombinase–in-
ducible mouse model of JAK2-V617F–driven MPN. These 
JAK2-V617F mice develop ET or PV phenotypes depending 
on the expression levels of JAK2-V617F in hematopoietic 
cells (Tiedt et al., 2008). Recently, we showed that hemato-
poietic stem cells (HSCs) expressing JAK2-V617F are capable 
of inducing clonal MPN in single cell transplantation (Lund-
berg et al., 2014b), albeit with low efficiency. This suggests 
that additional mutations, such as in Ezh2, may synergize with 
JAK2-V617F in MPN disease initiation.
Ezh2 functions as a core component of the polycomb 
repressive complex 2 (PRC2), which consists of three ad-
ditional subunits, Eed (embryonic ectoderm development), 
Suz12 (suppressor of zeste 12 homologue), and the histone 
binding protein RBBP4. PRC2 methylates lysine 27 on his-
tone H3 (H3K27me3). Ezh2 knockout mice are early em-
bryonic lethal (O’Carroll et al., 2001), but several conditional 
knockout strains have been generated that allow inactivating 
Ezh2 function in adult mice using inducible Cre-loxP sys-
tems (Hirabayashi et al., 2009; Neff et al., 2012). Conditional 
knockout of Ezh2 in adult hematopoiesis has revealed that 
Ezh2 is dispensable for the maintenance of long-term HSCs 
(LT-HSCs), most likely because of expression of Ezh1, a close 
homologue of Ezh2 that associates with Eed and Suz12 to 
form an alternative PRC2 complex that partially com-
pensates for the loss of Ezh2 (Xie et al., 2014). Here we 
studied JAK2-V617F and Ezh2 double mutant mice in Cre- 
inducible conditional systems to assess the functional conse-
quences in hematopoiesis.
RES ULTS
To assess the functional effects of Ezh2 loss on MPN phe-
notypes, we interbred mice with a conditional knockout al-
lele of Ezh2 (Neff et al., 2012) with inducible JAK2-V617F 
transgenic mice (hereafter called V617F; Tiedt et al., 2008). 
We first used the interferon-inducible MxCre system (Kühn 
et al., 1995) to delete one or both copies of Ezh2 and simul-
taneously induce expression of JAK2-V617F. Heterozygous 
loss of Ezh2 in V617F mice resulted in a trend toward more 
pronounced thrombocytosis and neutrophilia and initially 
also higher hemoglobin values than V617F alone (Fig. 1 A). 
V617F mice with homozygous loss of Ezh2 exhibited ele-
vated hemoglobin, thrombocytosis, and neutrophilia already 
at the time of induction by polyinosine-polycytosine (pIpC), 
consistent with leaky Cre expression. V617F;Ezh2Δ/Δ mice 
showed poor survival, whereas most of the V617F;Ezh2+/Δ 
mice survived until they were sacrificed at 28 wk (Fig. 1 A, 
right). Loss of Ezh2 in the absence of V617F had no effect on 
blood counts and did not affect survival. We repeated these 
experiments with the tamoxifen-inducible SclCreER system 
(Göthert et al., 2005). None of the mice showed an MPN 
phenotype before tamoxifen administration. The MPN phe-
notype appeared with a latency of ∼10 wk from the start 
of tamoxifen, and around this time the first deaths occurred 
(Fig.  1  B). Overall, the steepness of decline in survival of 
V617F;Ezh2Δ/Δ mice was comparable between MxCre- and 
SclCre-induced mice, although we cannot exclude that pIpC 
injections in MxCre;V617F;Ezh2Δ/Δ mice that already dis-
played MPN at the time of the injections might have had 
an additional negative impact on survival. The blood counts 
in SclCre-induced mice were comparable or slightly more 
pronounced than with the MxCre system (Fig. 1 B). JAK2-
V617F with homozygous loss of Ezh2 resulted in PMF with-
out a preceding polycythemic phase. Ezh2 mRNA expression 
was reduced to ∼50% in Ezh2+/Δ mice and strongly decreased 
in Ezh2Δ/Δ mice (Fig. 1 C). This reduction was paralleled by 
a decrease in Ezh2 protein and histone H3 methylation on 
lysine 27 (H3K27me3; Fig. 1 D). Ubiquitination of histone 
H2A on lysine 119 (H2AK119Ub), a marker for the activity 
of the PRC1 complex, was not increased in V617F;Ezh2Δ/Δ 
mice. All mice expressing V617F displayed splenomegaly, but 
no differences were observed in V617F mice with or without 
Ezh2 deletion (Fig. 1 E). Cellularity in BM was increased in 
V617F mice but markedly decreased in V617F;Ezh2Δ/Δ mice 
(Fig.  1  F). Furthermore, the numbers of circulating c-kit+ 
progenitors cells were strongly increased in V617F;Ezh2Δ/Δ 
mice (not depicted). The decrease in BM cellularity with an 
increase in circulating progenitor cells and a fall in hemoglo-
bin over time in V617F;Ezh2Δ/Δ mice is compatible with MF 
and is reminiscent of changes typically observed in patients 
with PMF with increased numbers of circulating CD34+ cells 
(Barosi et al., 2001). At 16 wk, all V617F mice, with or with-
out Ezh2 loss, showed typical histopathological features of 
MPN, with trilineage hyperplasia and increased numbers of 
atypical megakaryocytes, together with destruction of normal 
splenic architecture by infiltrates of highly atypical hemato-
poiesis (Fig. 1, G and H). Loss of Ezh2 in V617F mice accen-
tuated the hyperproliferation of the megakaryocytic lineage 
and resulted in a marked increase in reticulin fibers in BM 
and spleen, most prominently seen in V617F;Ezh2Δ/Δ mice, 
which also displayed an increase in collagen fibers and osteo-
sclerosis (not depicted). These changes were not observed in 
Ezh2+/Δ or Ezh2Δ/Δ mice with WT Jak2. Thus, heterozygous 
loss of Ezh2 accelerated the transition from PV to MF and 
homozygous loss of Ezh2 appears to directly lead to PMF, 
without a preceding polycythemic phase. None of the mice 
showed transformation to acute leukemia.
Analysis of the progenitor and stem cell compartments 
by flow cytometry revealed an increase of phenotypic LT-
HSCs and short-term HSCs (ST-HSCs) in BM and spleen 
of all genotypes expressing V617F (Fig. 2 A). Furthermore, 
multipotential progenitors (MPPs) and lineage-negative Sca-1+ 
c-kit+ (LSK) cells were increased in spleen, while a trend to-
ward increased LSKs was also noted in BM (Fig. 2 A). Hetero-
zygous deletion of Ezh2 on the V617F background increased 
LT-HSCs in BM and spleen, whereas homozygous deletion 
of Ezh2 on the V617F background was associated with in-
 o
n
 August 26, 2016
jem.rupress.org
D
ow
nloaded from
 
Published July 11, 2016
1481JEM Vol. 213, No. 8
Figure 1. Analysis of V617F;Ezh2 double mutant mice. (A) Time course of blood counts and survival of MxCre mice induced with pIpC (yellow arrows). 
The color code for the different genotypes is the same as indicated in C–F. The gray horizontal bars indicate the normal range for the blood values. Survival 
probability was calculated by the Kaplan-Meier method. The means of the values ± SEM are plotted (n = 4 for MxCre;GFP, n = 6 for MxCre;Ezh2+/Δ;GFP, 
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creased LT-HSCs in spleen and increased ST-HSCs in BM and 
MPPs in spleen (Fig. 2 A). Loss of Ezh2 on WT Jak2 back-
ground caused no significant changes in the HSC compart-
ments. Analysis of the more mature progenitor compartments 
(Fig. 2 B) showed that V617F alone increased megakaryocyte 
progenitors (MkPs) and megakaryocytes in spleen, whereas 
a prominent decrease in erythroid precursors occurred in 
BM, compensated by a strong increase of erythroid precur-
sors in spleen (Fig. 2 B). Homozygous loss of Ezh2 displayed 
a significant increase of MkPs and megakaryocytes and also 
megakaryocyte erythroid progenitors (MEPs) but decreased 
erythroid precursors in spleen (Fig.  2  B). Thus, heterozy-
gous and homozygous loss of Ezh2 on V617F background 
expanded the early HSC and progenitor compartment and 
favored megakaryopoiesis over erythropoiesis. Plasma levels 
of Tpo were decreased in mice expressing V617F compared 
with mice expressing WT Jak2 (Fig. 2 C). Loss of Ezh2 on 
V617F background further reduced the Tpo plasma levels, 
consistent with autoregulation of Tpo by the increased plate-
let and megakaryocyte mass. Interestingly, TGFβ in plasma 
showed a trend toward the highest levels in V617F;Ezh2Δ/Δ 
mice, consistent with the role of TGFβ as a mediator of MF.
To eliminate potential effects of Ezh2 deletion in non-
hematopoietic tissues and to determine how the double mu-
tant cells compete with WT hematopoiesis, we transplanted 
noninduced LSK cells together with WT BM competitor 
cells (Fig.  3). To allow monitoring of hematopoietic cells 
that carry the JAK2 and/or Ezh2 mutations, we crossed these 
strains with the UBC-GFP strain (Schaefer et al., 2001) and 
obtained donor mice that coexpressed GFP in the same cells 
(V617F;GFP or V617F;Ezh2;GFP). Both V617F;Ezh2+/Δ and 
V617F;Ezh2Δ/Δ mice showed a competitive advantage in the 
platelet and neutrophil lineages compared with V617F mice, 
whereas the differences in the erythroid lineage were minor 
(Fig. 3 A). The same conclusions were reached in competitive 
transplantations of BM cells from SclCre;V617F;GFP mice 
with heterozygous and homozygous loss of Ezh2 (Fig. 3 B).
To determine whether loss of Ezh2 also synergizes 
with JAK2-V617F in MPN disease initiation from single 
cells, we performed competitive transplantations at limiting 
dilutions (Fig. 4). We used the approach previously established 
for studying V617F mice (Lundberg et al., 2014b). Because 
the majority of MPN patients with Ezh2 mutations remain 
heterozygous and the V617F;Ezh2Δ/Δ mice show early 
lethality, we performed limiting dilutions with BM cells from 
heterozygous V617F;Ezh2+/Δ mice (Fig. 4 A). The numbers 
of phenotypic LT-HSCs in V617F and V617F;Ezh2+/Δ 
mice were increased two- to threefold compared with WT 
controls (Fig.  4  B). To obtain on average one HSC per 
transplant, we therefore reduced the number of BM cells 
from MxCre;V617F;GFP and MxCre :V617F;Ezh2+ /Δ;GFP 
donor mice to 8,000 cells per recipient, whereas 20,000 cells 
were used for the other genotypes. The time course of the 
blood counts and chimerism is summarized in Fig. 4 C. Data 
for each genotype was arranged in vertical columns. The 
frequencies of reconstitution, defined as chimerism >1% in 
Gr1-positive peripheral blood cells 22 wk after transplantation, 
are summarized in Table 1. Recipients of limiting dilutions of 
BM cells from V617F;GFP mice showed a high degree of tri-
lineage chimerism, but only a few of them developed MPN 
phenotype with mostly ET characteristics. The recipients of 
BM from V617F;Ezh2+/Δ;GFP mice reconstituted at higher 
frequencies and in most cases showed a PV phenotype (Fig. 4 C 
and Table 1). Recipients of Ezh2+/Δ;GFP BM with WT Jak2 
showed increased frequency of reconstitution (Table 1), but 
only few of them showed chimerism above 20% (Fig. 4 C). 
BM cellularity between V617F and V617F;Ezh2+/Δ mice was 
comparable (Fig.  4  D), but only the V617F;Ezh2+/Δ mice 
displayed splenomegaly (Fig. 4 E). In line with our previous 
study (Lundberg et al., 2014b), analysis of the percentages of 
the V617F;GFP-positive cells in hematopoietic progenitor 
and stem cell compartments in BM revealed that mice with 
MPN phenotype retained a high degree of GFP chimerism in 
the LT-HSC compartment, in contrast to mice without MPN 
n = 3 for MxCre;Ezh2Δ/Δ;GFP, n = 3 for MxCre;V617F;GFP, n = 4 for MxCre;V617F;Ezh2+/Δ;GFP, and n = 5 for MxCre;V617F;Ezh2Δ/Δ;GFP). (B) Analysis of 
V617F;Ezh2 double mutant mice using the inducible SclCre system. Time course of blood counts of mice induced with tamoxifen injections for 5 wk with 
1-wk break (orange horizontal bars). The means of the values ± SEM are plotted (n = 6 for SclCre, n = 13 for SclCre;Ezh2+/Δ, n = 8 for SclCre;Ezh2Δ/Δ, n = 9 
for SclCre;V617F, n = 12 for SclCre;V617F;Ezh2+/Δ, and n = 14 for SclCre;V617F;Ezh2Δ/Δ). The same color code for the different genotypes is used. (C) A 
subset of mice was sacrificed at 12 wk after tamoxifen induction. Expression of Ezh2 mRNA was determined by real-time PCR in total BM and is shown 
in arbitrary units with WT (wt) control BM set to the value of 1. The group sizes were n = 5 for SclCre, n = 5 for SclCre;Ezh2+/Δ, n = 4 for SclCre;Ezh2Δ/Δ, n 
= 4 for SclCre;V617F, n = 5 for SclCre;V617F;Ezh2+/Δ, and n = 5 for SclCre;V617F;Ezh2Δ/Δ. (D) Western blots of total BM cell lysates probed with antibodies 
against Ezh2, β-actin, H3K27me3, total histone H3, H2AK119Ub, and total H2A are shown. Genotypes are indicated above the corresponding lanes (n = 3 
for each group). This experiment was performed twice. (E and F) Spleen weight (E) and BM cellularity (F) are shown at 12 wk after tamoxifen (n = 9 or 12 for 
SclCre, n = 7 or 12 for SclCre;Ezh2+/Δ, n = 10 or 13 for SclCre;Ezh2Δ/Δ, n = 5 or 8 for SclCre;V617F, n = 6 or 10 for SclCre;V617F;Ezh2+/Δ, and n = 6 or 8 for 
SclCre;V617F;Ezh2Δ/Δ for spleen weight or BM cellularity). This experiment was performed four times. (C, E, and F) Results are presented as means ± SEM. 
(G and H) Histopathology of BM and spleen taken at 16 wk after start of tamoxifen injection. The sections were stained with hematoxylin and eosin (H&E) 
or with the Gömöri stain (Göm). The grade of MF is indicated under the corresponding pictures. Grading of MF was performed on three mice per group, and 
one representative mouse per genotype is shown. Bars: (black) 500 µm; (yellow) 50 µm; (blue) 20 µm; (orange) 10 µm. Statistical analysis was conducted 
using the Student’s t test or one-way ANO VA with Bonferroni’s post-hoc multiple comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Red asterisks 
indicate significance between control and V617F. Light blue asterisks indicate significance between V617F and V617F;Ezh2+/Δ. Dark blue asterisks indicate 
significance between V617F and V617F;Ezh2Δ/Δ.
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Figure 2. Flow cytometric analysis of stem cell and progenitor compartments in BM and spleen of tamoxifen-inducible JAK2-V617F and Ezh2 
mutant mice. (A) Frequencies of LT-HSCs, ST-HSCs, MPPs, and LSK cells are shown. The top panel shows analysis of BM, and the bottom panel analysis of 
spleen cells for the different genotypes, as indicated (n = 5 for SclCre, n = 4 for SclCre;Ezh2+/Δ, n = 6 for SclCre;Ezh2Δ/Δ, n = 6 for SclCre;V617F, n = 4 for 
SclCre;V617F;Ezh2+/Δ, and n = 4 for SclCre;V617F;Ezh2Δ/Δ) This experiment was performed three times. (B) Frequencies of MkPs, megakaryocytes, MEPs, and 
erythroid precursors are shown for BM (top) and spleen (bottom). The same mice as in A were analyzed. (C) Plasma concentrations of Tpo and TGFβ from 
tamoxifen-inducible JAK2-V617F and Ezh2 mutant mice were measured by ELI SA (n = 5 per group for TPO; n = 4 for SclCre, n = 4 for SclCre;Ezh2+/Δ, n = 5 
for SclCre;Ezh2Δ/Δ, n = 3 for SclCre;V617F, n = 3 for SclCre;V617F;Ezh2+/Δ, and n = 5 for SclCre;V617F;Ezh2Δ/Δ for TGFβ). Statistical analysis was conducted 
using the Student’s t test or one-way ANO VA with Bonferroni’s post-hoc multiple comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Results are 
presented as means ± SEM.
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phenotype, where the expansion of V617F;GFP chimerism 
often occurred at later stages of differentiation (Fig. 4 F). The 
same pattern was also observed in three out of four of the 
V617F;Ezh2+/Δ;GFP mice with MPN phenotype that were 
analyzed (Fig.  4  F, right). This suggests that in some cases 
heterozygous loss of Ezh2 may help to overcome restrictions 
that prevent developing MPN when the V617F clone has 
not fully expanded in the LT-HSC compartment. Overall, 
these results show that heterozygous loss of Ezh2 synergized 
with V617F also in monoclonal MPN disease initiation 
at limiting dilutions.
To further examine the effects of the Ezh2 mutations 
on the LT-HSC compartment, we transplanted 50 LT-HSCs 
purified by FACS sorting from donor mice taken 12 wk after 
tamoxifen induction and assessed their functional capacity 
to reconstitute and initiate MPN in lethally irradiated re-
cipients (Fig. 5). We used 106 WT BM cells as competitors 
(Fig. 5 A). Because of reduced survival of mice reconstituted 
with V617F;Ezh2Δ/Δ;GFP BM, we terminated the experi-
ment at 24 wk and the results of analysis at 16 wk are shown 
(Fig. 5 B). Only 4/10 recipients (40%) that received purified 
LT-HSCs from V617F;GFP reconstituted with a chimerism 
of >1% in Gr1-positive cells, and only 2 of the chimeric mice 
also showed an MPN phenotype. This result confirms our 
previous findings, which showed that the functional stem cell 
compartment in V617F mice is shifted toward cells with a 
Figure 3. Competitive BM transplantations. (A) Transplantation of noninduced LSK cells (1,500 FACS-sorted cells) from MxCre mouse mutants coex-
pressing GFP mixed with WT BM cells (1.5 × 106). Time course of blood counts and survival of transplanted mice after induction with pIpC (yellow arrows) are 
shown in the top panel. The bottom panel shows the chimerism assessed by the percentage of GFP-positive cells for the erythroid (TER119), platelet (CD61), 
and granulocytic (Gr1) lineages. The experiment was performed twice. One experiment is shown with n = 5 for MxCre;GFP, n = 5 for MxCre;Ezh2+/Δ;GFP, 
n = 3 for MxCre;Ezh2Δ/Δ;GFP, n = 5 for MxCre;V617F;GFP, n = 5 for MxCre;V617F;Ezh2+/Δ;GFP, and n = 3 for MxCre;V617F;Ezh2Δ/Δ;GFP. (B) Competitive trans-
plantation with noninduced SclCre mutant BM cells coexpressing GFP (0.25 × 106) mixed at 1:3 ratio with WT BM cells (0.75 × 106). Activation of V617F and 
knockout of the floxed Ezh2 alleles were induced with tamoxifen injections for 5 wk with 1-wk break (orange horizontal bars). The time course of the blood 
counts (top) and the corresponding chimerism in peripheral blood (bottom) are shown (n = 8 for SclCre, n = 8 for SclCre;Ezh2+/Δ, n = 8 for SclCre;Ezh2Δ/Δ, 
n = 6 for SclCre;V617F, n = 6 for SclCre;V617F;Ezh2+/Δ, and n = 6 for SclCre;V617F;Ezh2Δ/Δ). Statistical analysis was conducted using one-way ANO VA with 
Bonferroni’s post-hoc multiple comparison test. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Red asterisks indicate significance between control and V617F. Light 
blue asterisks indicate significance between V617F and V617F;Ezh2+/Δ. Dark blue asterisks indicate significance between V617F and V617F;Ezh2Δ/Δ. Gray 
horizontal bars indicate the normal range for C57BL/6 mice. Results are presented as means ± SEM.
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lineage-intermediate immunophenotype (Lundberg et al., 
2014b). Interestingly, heterozygous loss of Ezh2 on V617F 
background increased the frequency of reconstitution to 5/9 
recipients (56%), and 4/5 mice with chimerism also displayed 
an MPN phenotype (Fig. 5 B). The effect of homozygous loss 
of Ezh2 on V617F background was even more pronounced, 
Figure 4. Competitive limiting dilution 
transplantations of BM cells from mouse 
mutants. (A) The schematic drawing shows 
the design of the experiment. (B) The frequency 
of phenotypic LT-HSCs was determined by flow 
cytometry in the individual donor mice that 
were previously induced with pIpC 5 wk before 
the transplantation. (C) Time course of blood 
counts and chimerism determined by GFP in 
peripheral blood is shown for the four differ-
ent genotypes as indicated. This experiment 
was performed once with a total of 141 re-
cipient mice. Individual mice showing chimer-
ism >1% at 22 wk in Gr1-positive lineage are 
shown with colored symbols and lines (n = 19 
for MxCre;GFP, n = 40 for MxCre;Ezh2+/Δ;GFP, 
n = 41 for MxCre;V617F;GFP, and n = 41 for 
MxCre;V617F;Ezh2+/Δ;GFP). Gray horizontal 
bars indicate the normal range for C57BL/6 
mice. (D and E) BM cellularity (D) and spleen 
weights (E) of five V617F and six V617F;Ezh2+/Δ 
mice at 30 wk after transplantation. Numbers 
in red indicate mice with the MPN phenotype, 
and numbers in black are mice without the 
MPN phenotype. (F) Graph showing the evo-
lution of V617F;GFP and V617F;Ezh2+/Δ;GFP 
cells at different stages of HSC, progenitor, or 
erythroid cell differentiation. These mice were 
sacrificed 30 wk after transplantation. The 
percentages of GFP cells indicate the size of 
the mutant clone (colored area). The mice with 
the MPN phenotype are also identified by their 
numbers in red color in the hemoglobin or 
platelet charts in C. CD71+/TER119+, erythroid 
precursor cells; Ec, erythrocytes.
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and 9/9 recipient showed high chimerism and displayed an 
ET phenotype (Fig. 5 B), while their survival was reduced 
(Fig. 5 C). The frequencies of reconstitution and MPN dis-
ease initiation is summarized in Fig. 5 D. Homozygous loss 
of Ezh2 on Jak2 WT background reduced the frequency of 
reconstitution (5/8 recipients) compared with WT BM cells 
(8/9 recipients), but at the same time resulted in a shift to-
ward higher percentage of myeloid cells in peripheral blood 
(Fig. 5 E). V617F alone also resulted in a myeloid bias, and 
the combination of V617F;Ezh2Δ/Δ shifted the percentages 
almost completely toward myeloid cells (Fig. 5 E). Compar-
ison of the platelet and erythrocyte chimerisms in peripheral 
blood for all recipients of BM from Ezh2 mutants on Jak2 
WT background is shown in Fig. 5 F. Homozygous loss of 
Ezh2 alone already leads to a shift toward thrombopoiesis.
To study the mechanism of how loss of Ezh2 contrib-
utes to enhancement of the MPN phenotype, we compared 
the mRNA expression profiles of hematopoietic cells with or 
without mutations in JAK2 and Ezh2 by RNA sequencing. 
LT-HSCs and MEP cells were FACS sorted from groups of 
four to six mice per genotype 10 wk after tamoxifen induc-
tion, and RNA was used to prepare libraries for sequencing 
on Illumina NextSeq500. The mutant versus WT Jak2 is the 
dominant parameter that divides the heat map of LT-HSCs 
into two groups (Fig. 6 A), and this influence is also repre-
sented in the principal component analysis (PCA) along the 
principal component 1 axis (Fig. 6 B, left). In MEPs, the influ-
ence of the Jak2 genotype is less prominent. Instead, unsuper-
vised clustering reveals a strong influence of the homozygous 
loss of Ezh2, which defines two distinct groups in the heat 
map, one with WT Jak2 and one with V617F (Fig. 6 A, right). 
The effects of heterozygous loss of Ezh2 were less prominent 
in the clustering and the groups of V617F and V617F;E-
zh2+/Δ MEPs appear to be rather heterogeneous. In PCA of 
the MEP data, WT Jak2 versus V617F is the dominant factor 
(principal component 1), explaining 43% of the variation in 
log2-fold change (Fig. 6 B, right). The second most promi-
nent effect in the PCA (principal component 2) is observed 
between homozygous loss of Ezh2 versus heterozygous or 
WT Ezh2, which accounts for 21% of the variation in log2-
fold change. Competitive gene set enrichment analysis com-
paring LT-HSCs from V617F;Ezh2Δ/Δ versus V617F mice 
revealed interferon-γ and interferon-α signatures (Fig. 6 C). 
Using self-contained gene set testing, we also found posi-
tive enrichment of a fetal liver HSC-specific gene signature 
(Fig. 6 C, right). In LT-HSCs, the largest number of differen-
tially expressed genes was found between WT cells and cells 
expressing V617F (Fig. 6 D). There are fewer differentially ex-
pressed genes in V617F-expressing cells with different Ezh2 
genotypes, and homozygous loss of Ezh2 had a much stronger 
effect than heterozygous loss. Few differences in gene expres-
sion were detected between different Ezh2 genotypes on a 
WT Jak2 background. In MEPs, the largest number of dif-
ferentially expressed genes (with P ≤ 0.05) is observed in 
genotypes that involve comparisons with homozygous loss of 
Ezh2 both on WT Jak2 and V617F background (Fig. 6 D). 
The second largest effect is seen in the comparison between 
V617F and WT Jak2, whereas the heterozygous Ezh2 showed 
the fewest changes both in comparison with WT Jak2 and in 
comparison between V617F and V617F;Ezh2+/Δ. The top 10 
differentially expressed genes for the comparisons between 
WT and Ezh2Δ/Δ and V617F with V617F;Ezh2Δ/Δ were or-
dered according to the absolute fold change in expression 
and are shown in Fig. 6 E. There was no overlap among the 
top 10 gene lists from LT-HSCs and MEP, except for Lin28b, 
which showed the highest fold changes in both LT-HSCs and 
MEPs. The complete list of differentially expressed genes is 
provided in Tables S1 and S2. Lin28b, together with let-7 and 
Hmga2, plays an important role in regulating HSC self-re-
newal (Oguro et al., 2012; Copley et al., 2013). The log2 ex-
pression levels of Lin28b and its downstream gene Hmga2 
are plotted in Fig. 6 F. In LT-HSCs, Lin28b was significantly 
elevated only in V617F;Ezh2Δ/Δ cells, whereas in MEPs both 
WT Jak2;Ezh2Δ/Δ and V617F;Ezh2Δ/Δ cells showed increased 
Lin28b (Fig. 6 F). Hmga2 expression was unchanged in LT-
HSCs (not depicted). However, Hmga2 expression was sig-
nificantly elevated in MEPs from mice with Ezh2Δ/Δ on WT 
Jak2 or V617F backgrounds (Fig. 6 F, right).
Up-regulated expression of Hmga2 was previously linked 
to increased megakaryopoiesis and MF (Oguro et al., 2012). We 
determined the mRNA expression levels of HMGA2 in gran-
ulocytes from MPN patients with EZH2 mutations (Fig. 6 G). 
A trend toward higher expression of HMGA2 was observed in 
four patients with mutations in CALR that carried heterozy-
gous EZH2 mutations and were very high in one patient with 
mutated CALR and a homozygous EZH2 mutation. Patients 
with JAK2-V617F and homozygous EZH2 mutations also 
showed a trend toward higher HMGA2 expression. We also 
Table 1. Summary of competitive limiting dilution transplantation experiments
Genotype of donor mice Recipients n = Number of BM cells transplanted Frequency of long-term 
reconstitutiona
Mice with MPN phenotype
MxCre;GFP 19 20,000 2/19 (10%) 0
MxCre;Ezh2+/Δ;GFP 40 20,000 13/40 (32.5%) 1/13 (7.6%)
MxCre;V617F;GFP 41 8,000 6/41 (15%) 2/6 (33%)
MxCre;V617F;Ezh2+/Δ;GFP 41 8,000 16/41 (39%) 8/16 (50%)
The indicated numbers of BM cells were injected into lethally irradiated recipients.
aReconstitution was scored based on the presence of >1% GFP-positive cells in the peripheral blood Gr1+ cells at 22 wk after transplantation.
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examined expression of two other genes in patients’ granu-
locytes: IGF2BP3, a downstream target of Lin28b pathway, 
and Pcolce2, an up-regulated gene in the top 10 list of MEPs 
from mice with Ezh2Δ/Δ on WT and V617F backgrounds. 
Both showed a similar trend toward higher expression in MPN 
patients with EZH2 mutations. These data are consistent with 
a model in which the decrease of PRC2 activity through loss 
of Ezh2 ultimately results in gene expression changes that 
favor megakaryopoiesis but alone are insufficient to cause a 
thrombocytosis phenotype, unless JAK2-V617F is coexpressed.
The Lin28b–Let7–Hmga2 axis is an attractive candidate 
pathway to mediate the synergistic effect of loss of Ezh2 and 
expression of JAK2-V617F and on megakaryopoiesis. To de-
termine whether the promoters of Lin28b and Hmga2 are 
directly affected by the loss of Ezh2 activity, we performed 
chromatin immunoprecipitation (ChIP) with antibodies 
against H3K27me3 followed by quantitative PCR (qPCR) 
analysis using primers for the promoter regions of Lin28b and 
Hmga2 (Fig. 7 A). We found that both the Lin28b and Hmga2 
promoters exhibited significantly reduced H3K27me3 depo-
Figure 5. Competitive transplantation of purified LT-HSCs. (A) Schematic drawing shows the design of the experiment. The donor mice were induced 
with tamoxifen 10 wk before they were sacrificed. LT-HSCs were isolated using FACS with the antibodies as indicated. For transplantation, 50 mutant LT-
HSCs coexpressing GFP were mixed with 106 WT BM cells and injected into lethally irradiated recipient mice. The experiment was performed twice with a 
total of 79 recipient mice. One experiment with n = 9 for SclCre;GFP, n = 9 for SclCre;Ezh2+/Δ;GFP, n = 8 for SclCre;Ezh2Δ/Δ;GFP, n = 10 for SclCre;V617F;GFP, 
n = 9 for SclCre;V617F;Ezh2+/Δ;GFP, and n = 9 for SclCre;V617F;Ezh2Δ/Δ;GFP is shown. (B) Blood counts and GFP chimerism of BM chimera mice at 16 wk 
after transplantation are shown. Individual mice that displayed the MPN phenotype are marked in red color. Horizontal lines indicate the mean of the values. 
Gray horizontal bars indicate the normal range for C57BL/6 mice. (C) Survival probability was calculated by the Kaplan-Meier method. (D) Analysis of recon-
stitution by the mutant LT-HSCs. The bars represent the percentages of reconstitution, assessed by GFP for each of the genotypes. Failure to reconstitute 
was defined as <1% GFP-positive cells in the Gr1 lineage in the peripheral blood at 16 wk after transplantation. Blue bars indicate reconstitution without 
the MPN phenotype, whereas red portions of the bars indicate the proportion of mice with the MPN phenotype. (E) Analysis of lineage distribution in 
GFP-positive cells in peripheral blood. Results are presented as means ± SEM. (F) Correlation between platelet (Plt) chimerism and erythroid (Ery) chimerism 
in peripheral blood of mice with Ezh2 mutations on WT Jak2 background.
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Figure 6. Gene expression analysis by RNA sequencing of LT-HSCs and MEPs. (A) Unsupervised clustering of differentially expressed genes (P ≤ 
0.05; log2-fold changes >1.5). Each column represents data from one individual mouse. The color code for the genotypes of the individual mice is the 
same as in B. (B) PCA. The data for LT-HSCs and MEPs were derived from two independent experiments and combined (n = 4 or 5 for SclCre, n = 7 or 4 for 
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sition in sorted LSK and MEP cells from Ezh2Δ/Δ mice, sug-
gesting that both are directly affected by the loss of Ezh2. 
Next, we examined the effects of forced expression of Lin28b 
or Hmga2 in vitro by retroviral transduction and culture of 
FACS-sorted LT-HSCs from WT or V617F-expressing BM 
(Fig. 7 B). Expression of Hmga2 in LT-HSCs with WT Jak2 
expanded cell numbers in culture (Fig.  7 B, phase contrast 
picture in top row) and led to the presence of megakaryo-
cytes (Fig. 7 B, left). Co-expression of Hmga2 and V617F ex-
panded the numbers of megakaryocytes. Similar results were 
also seen after retroviral transduction of Lin28b.
To determine the effects of forced expression of Hmga2 
and Lin28b in vivo, we retrovirally transduced FACS-sorted 
LT-HSCs from WT or V617F-expressing LT-HSCs and trans-
planted lethally irradiated C57BL/6 recipients (Fig. 7 C). We 
injected ∼150 retrovirally transduced LT-HSCs together with 
250,000 WT BM cells per mouse in three independent exper-
iments. Because the retroviral vector contains a GFP cassette, 
the offspring of the transduced can be traced by the presence 
of GFP. Analysis of blood counts and GFP chimerism is shown 
at 8 wk after transplantation. Mice from all three experiments 
that displayed >5% GFP chimerism are shown in Fig. 7 C. 
Increased chimerism was observed in mice transplanted with 
Hmga2-transduced BM from WT mice, but the blood counts 
remained unchanged. Hmga2-transduced BM from V617F 
mice showed higher chimerism and higher platelet counts 
compared with vector control (MIGR). A trend toward in-
creased hemoglobin and neutrophil counts was also noted. In 
contrast, forced expression of Lin28b resulted in lower chi-
merism when BM from WT mice was used for transplanta-
tion. Lin28b in combination with V617F expression resulted 
in very few recipient mice that reached any GFP chimerism, 
and only one mouse showed chimerism >5%. This mouse 
had normal blood counts. Thus, our functional data suggest 
that Hmga2 expression in Ezh2-deficient mice is linked to 
reduced deposition of H3K27me3 in its promoter. The in-
creased expression of Hmga2 resulted in augmented cell 
production in vitro and in increased chimerism and platelet 
counts in vivo. Lin28b had similar effects when transduced 
cells were cultured in vitro. However, in vivo Lin28b did not 
show a synergistic effect with V617F, and its potential role in 
mediating the synergism between V617F and loss of Ezh2 is 
unclear. The synergism between V617F and loss of Ezh2 is 
likely to be mediated by a concerted action of several genes 
that are altered in their expression, and our data indicate that 
Hmga2 is one of these downstream targets.
Inhibitors of Ezh2 are currently in clinical trials for treat-
ment of patients with lymphomas. Because our results show 
that genetic ablation of Ezh2 accelerated MPN in V617F-ex-
pressing mice, we tested whether pharmacological inhibition 
of Ezh2 might also have an MPN disease–promoting effect. 
We examined the effects of the Ezh2 inhibitor GSK126 in 
our previously described competitive transplantation model 
with V617F;GFP BM cells and WT competitor cells that 
allows monitoring of changes in mutant allele burden and 
in blood counts (Kubovcakova et al., 2013). Recipient mice 
transplanted with V617F;GFP received GSK126 by gavage 
for 34 d. Mice treated with the higher dosing regimen (150 
mg/kg six times per week) displayed an increase in plate-
lets (Fig. 7 D), mimicking the genetic ablation of Ezh2. We 
were unable to extend the duration of the treatment past 34 
d because of toxicity (weight loss). Nevertheless, this result is 
consistent with the pronounced thrombocytosis when Ezh2 
is genetically ablated in V617F-expressing mice. Caution 
should therefore be exercised in consideration of pharmaco-
logical inhibition of Ezh2 in the setting of MPN.
DIS CUS SION
Our data provide evidence for functional synergism between 
JAK2-V617F and heterozygous or homozygous loss of Ezh2 
in hematopoiesis in vivo. The MPN phenotype induced by 
V617F alone was accentuated in double mutant mice with 
V617F and heterozygous or homozygous loss of Ezh2. Pe-
ripheral blood counts, notably platelets and neutrophils, were 
increased, survival was reduced, and a higher degree of MF 
was observed in heterozygous V617F;Ezh2+/Δ mice, and 
these alterations were even more pronounced in homozygous 
V617F;Ezh2Δ/Δ mice (Fig.  1). Loss of Ezh2 on a Jak2 WT 
background did not affect blood counts, survival, or histology.
Comparison of the progenitor and stem cell compart-
ments between V617F and V617F;Ezh2 mutant mice revealed 
a slight increase of LT-HSCs in homozygous V617F;Ezh2Δ/Δ 
mice (Fig.  2  A), whereas a strong increase in MkPs and a 
decrease in erythroid precursors were noted (Fig. 2 B). These 
changes are in line with the alterations observed in periph-
eral blood of these mice. Although expansion of MEPs was 
observed in spleens of homozygous V617F;Ezh2Δ/Δ mice, this 
alteration may reflect increased activity of megakaryopoiesis 
SclCre;Ezh2+/Δ, n = 4 for SclCre;Ezh2Δ/Δ, n = 6 or 4 for SclCre;V617F, n = 8 or 6 SclCre;V617F;Ezh2+/Δ, and n = 6 for SclCre;V617F;Ezh2Δ/Δ for LT-HSCs or MEP 
analysis). Each dot represents data from one individual mouse. (C) Competitive gene set enrichment analysis for gene expression signatures of interferon-γ, 
interferon-α, and fetal liver HSCs in LT-HSCs of SclCre;V617F;Ezh2Δ/Δ compared with SclCre;V617F. (D) Plot showing the number of differentially expressed 
genes with cutoff of P ≤ 0.05. (E) Gene list of top 10 significant gene expression differences according to the absolute fold change. (F) Expression levels of 
Lin28b and Hmga2. Each dot represents data from one individual mouse. (G) Relative expression of HMGA2, IGF2BP3, and Pcolce2 determined by qPCR in 
granulocyte RNA from patients with MPN that carry mutations in EZH2 or CALR. Each dot represents data from one individual patient. The mutations in 
patient granulocyte were determined by allele-specific PCR (n = 4 for CALR mutation with WT EZH2, n = 4 for CALR mutation with heterozygous mutation 
of EZH2, n = 1 for CALR mutation with homozygous mutation of EZH2, n = 8 for JAK2V617F mutation with WT EZH2, n = 12 for JAK2V617F mutation with 
heterozygous mutation of EZH2, and n = 4 for JAK2V617F mutation with h homozygous mutation of EZH2). (F and G) Horizontal lines indicate the mean 
of the values. *, P < 0.05; ***, P < 0.001.
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of this bipotent progenitor population. Loss of Ezh2 on Jak2 
WT background had no significant effect on the progenitor 
and stem cell compartment compared with WT controls, ex-
cept for an increase of MEPs in BM (Fig. 2 B).
Synergism between JAK2-V617F and heterozygous loss 
of Ezh2 was also evident in BM transplantation experiments 
at limiting dilutions. BM grafts from heterozygous V617F;E-
zh2+/Δ mice that contained on average only a single HSC 
engrafted at higher frequencies and showed more frequently 
a MPN phenotype in lethally irradiated recipients than grafts 
from V617F mice (Fig. 4 and Table 1). Although expression 
of V617F alone resulted in a decrease of functional HSC ac-
tivity when 50 FACS-sorted LT-HSCs were transplanted in 
competition with WT BM cells, loss of Ezh2 on V617F back-
ground restored the reconstitution capacity and increased 
disease initiation potential of FACS-sorted LT-HSCs (Fig. 5). 
The reduced efficiency of phenotypic LT-HSCs from V617F 
mice for long-term reconstitution in transplantation experi-
ments was noted in our previous study and was accompanied 
by an expansion of stem cell activities in cells with lineage-in-
termediate Sca1+ c-kit+ immunophenotype (Lundberg et al., 
2014b). Overall, the synergistic effects of V617F and loss of 
Ezh2 manifested in expansion of the stem cell and progeni-
tor cell compartment with increased reconstitution and MPN 
disease initiation potential and shift of differentiation toward 
megakaryopoiesis at the expense of erythropoiesis.
The effects of conditional Ezh2 knockout in hematopoi-
esis have been previously studied. The tendency of increasing 
megakaryopoiesis was reported in conditional Ezh2 knock-
out on a WT Jak2 background. In one report, loss of Ezh2 
resulted in subtle thrombocytosis (Mochizuki-Kashio et al., 
2011). Thrombocytopenia in Mpl−/− mice was partially im-
proved in Mpl−/−;Ezh2Δ/Δ double mutant mice (Majewski et 
al., 2010). We did not observe thrombocytosis in our Ezh2Δ/Δ 
mice on a WT Jak2 background, but we noted increased MEPs 
in BM and a trend toward more megakaryocytes (Fig. 2 B) as 
well as a shift toward increased platelet chimerism in Ezh2Δ/Δ 
mice compared with WT controls (Fig. 5 F). Loss of Ezh2 
attenuated but did not prevent MLL-AF9–mediated acute 
myeloid leukemia (Neff et al., 2012). Although loss of Ezh2 
in the context of V617F accelerated disease, overexpression of 
Ezh2 has also been implicated in the progression of various 
types of human cancers (reviewed by Sauvageau and Sau-
vageau [2010] and Margueron and Reinberg [2011]), and a 
recurrent gain of function mutation in EZH2 (EZH2-Y641) 
has also been reported to occur in lymphomas (Morin et al., 
2010; Yap et al., 2011). Paradoxically, overexpression of Ezh2 
also enhances HSC self-renewal (Kamminga et al., 2006) and 
results in a myeloproliferative disorder with leukocytosis and 
splenomegaly (Herrera-Merchan et al., 2012). These findings 
are difficult to reconcile and likely reflect the complex and 
cell type–dependent roles of PRC2 complex. Indeed, several 
compensatory mechanisms have been described that come 
into effect when Ezh2 function is abolished, including com-
pensation by Ezh1, as well as noncanonical PRC2 functions 
that do not depend on H3K27me3 (Xie et al., 2014).
Gene expression analysis in LT-HSC and MEP cells re-
vealed strong effects of V617F over WT Jak2 and also strong 
effects of homozygous loss of Ezh2Δ/Δ (Fig.  6). In contrast, 
heterozygous Ezh2+/Δ had little influence on gene expression 
levels, despite showing functional synergism with V617F on 
the MPN phenotype in V617F;Ezh2+/Δ double mutant mice. 
Several genes highly up-regulated in MEPs from Ezh2Δ/Δ mice 
on Jak2 WT, as well as on a V617F background, have estab-
lished functions in hematopoiesis, including Lin28b, a negative 
regulator of let-7 microRNA biogenesis (Viswanathan et al., 
2008; Piskounova et al., 2011), which is up-regulated in many 
human tumors and cancer cell lines (Viswanathan et al., 2009). 
The Lin28b–let-7 pathway is involved in the regulation of 
HSC self-renewal in fetal and adult hematopoiesis (Copley et 
al., 2013). Hmga2 is an established target of let-7 and, when 
up-regulated, is linked to increased megakaryopoiesis and MF 
(Oguro et al., 2012). Hmga2 is highly expressed in some pa-
tients with PMF (Andrieux et al., 2004). We also found Hmga2 
to be up-regulated in MEPs from Ezh2Δ/Δ and V617F;Ezh2Δ/Δ 
mice (Fig. 6 F) and also in granulocytes from MPN patients 
with homozygous loss of EZH2 (Fig. 6 G). These data sug-
gested a possible function of the Lin28b–let7–Hmga2 axis in 
mediating the observed hyperproliferation of the megakaryo-
cytic lineage and acceleration of MF in our mouse model.
ChIP-qPCR data demonstrated that the Lin28b and 
Hmga2 promoters in LSK and MEP cells exhibit reduced 
Figure 7. Functional analysis of Lin28b and Hmga2. (A) ChIP from LSK and MEP cells from mice with the indicated genotypes (n = 4 per each group) 
was performed with antibodies against H3K27me3 followed by qPCR analysis using primers for the promoter regions of Lin28b and Hmga2. Data pooled 
from two independent experiments are shown. (B) Growth of CD150+CD48−LSK (LT-HSC) transduced with the Hmga2 or Lin28b retrovirus. 50 LT-HSCs were 
transduced with either the vector (MIGR) or Hmga2 or Lin28b retrovirus and cultured in the presence of SCF and TPO. Colony picture and morphology of 
LT-HSCs at day 8 of culture are shown. The experiment was independently performed three times, and one representative picture is shown. Bars: (top and 
middle) 50 µm; (bottom) 100 µm. (C) Peripheral blood cell counts and donor chimerism of recipients repopulated with WT Jak2 or V617F LT-HSCs trans-
duced with the indicated vector. Recipient mice with >5% GFP positive chimerism are shown. The experiment was independently performed three times, 
and combined data are shown (n = 12 for MIGR transduction in WT LT-HSCs, n = 13 for Hmga2 in WT LT-HSCs, n = 6 for Lin28b in WT LT-HSCs, n = 9 for 
MIGR transduction in JAK2V617F LT-HSCs, n = 6 for Hmga2 transduction in JAK2V617F LT-HSCs, and n = 1 for Lin28b transduction in JAK2V617F LT-HSCs). 
Each dot represents data from one individual mouse. Horizontal lines indicate the mean of the values. (D) Pharmacological effect of Ezh2 inhibitor GSK-126. 
V617F;GFP BM cells were transplanted with WT BM cells in a 1:10 ratio. Recipient mice received GSK-126 by gavage at a dose of either 300 mg/kg twice per 
week (blue lines and dots) or 150 mg/kg six times per week (red lines and dots) for 34 d (n = 4 per group). This experiment was performed once. Statistical 
analysis was conducted using the Student’s t test. *, P < 0.05; **, P < 0.01. Results are presented as means ± SEM.
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H3K27me3 deposition upon Ezh2 loss (Fig. 7 A), suggesting 
that both are normally repressed by Ezh2. Although forced 
expression of Lin28b in V617F-expressing cells increased cell 
numbers and megakaryocyte numbers during growth in vitro 
(Fig. 7 B), this effect was not observed in mice transplanted 
with retrovirally transduced BM cells in vivo (Fig. 7 C). In 
contrast, overexpressing Hmga2 promoted megakaryopoiesis 
both in vitro and in vivo, suggesting that increased expression 
of Hmga2 is a downstream event mediating synergism be-
tween V617F and loss of Ezh2.
Our data support the proposed tumor suppressor func-
tion of EZH2 in patients with MPN. The synergism between 
mutant JAK2-V617F and reduced Ezh2 activity in hema-
topoiesis is evident in heterozygous V617F;Ezh2+/Δ mice, 
which is consistent with the finding that most MPN patients 
with EZH2 mutations do not progress to homozygosity. The 
prospect of using Ezh2 inhibitors in the context of MPN may 
carry the risk of aggravating the disease.
MAT ERI ALS AND MET HODS
Transgenic mice. Mice with Cre-recombinase–inducible 
human JAK2-V617F transgene were generated directly in the 
C57BL/6 background in our laboratory (Tiedt et al., 2008). 
These V617F mice were crossed with mice with a conditional 
Ezh2 knockout allele, in which exons 16 and 17 are flanked 
by loxP sites (Ezh2fl/fl; Neff et al., 2012) to generate double 
mutant mice (V617F;Ezh2fl/fl). These mice were crossed with 
MxCre transgenic mice (Kühn et al., 1995) or SclCreER mice 
(Göthert et al., 2005) to obtain offspring that allow induc-
ible deletion of the floxed Ezh2 alleles and activation of the 
V617F transgene. Ezh2fl/fl, MxCre, SclCreER, and UBC-GFP 
mice had been backcrossed into the C57BL/6 background 
for 12 generations, and the purity of the C57BL/6 back-
ground was verified using a 1449 SNP Illumina BeadChip 
panel and the SNaP-Map Software at the DartMouse Speed 
Congenic Core Facility at The Geisel School of Medicine at 
Dartmouth. Cre expression in MxCre mutant mice was in-
duced by intraperitoneal injection of 300 µg pIpC three times 
every second day, and Cre expression in SclCre mutant mice 
was induced by intraperitoneal injection of 2 mg tamoxifen 
once daily for 4 wk, with a 1-wk break in the middle. The re-
cipient C57BL/6 mice used for competitive transplantations 
were purchased from Janvier Labs. All mice in this study were 
kept under specific pathogen–free conditions with free access 
to food and water in accordance to Swiss Federal Regula-
tions, and all experiments were performed in strict adherence 
to Swiss laws for animal welfare and approved by the Swiss 
Cantonal Veterinary Office of Basel-Stadt.
Competitive BM transplantations. For competitive transplan-
tations, mice were intercrossed with the UBC-GFP strain, 
and whole BM or fractionated hematopoietic cells were used 
as donor cells. This system allows tracking donor-derived he-
matopoiesis (chimerism) in all hematopoietic lineages in re-
cipient mice. Competitive whole BM transplantation was 
performed with 0.25 × 106 BM cells from 10-wk-old SclCre 
mutant mice without tamoxifen injection. Whole BM cells 
were transplanted intravenously into 10-wk-old female recip-
ient mice (C57BL/6N) irradiated with 12 Gray (Gy), to-
gether with 0.75 × 106 BM cells of WT mice. Tamoxifen was 
injected for 5 wk, starting 8 wk after transplantation, with 
1-wk break in the middle of the treatment. LT-HSC trans-
plantations were performed with 50 purified LT-HSCs from 
SclCre mutant mice 12 wk after tamoxifen injection together 
with 106 BM cells of WT mice. LSK transplantation was per-
formed with 1,500 purified LSK cells from MxCre mutant 
mice at 8 wk of age without pIpC injection together with 1.5 × 
106 BM cells of WT mice. For competitive transplantations at 
limiting dilution, 20,000 total BM cells from MxCre;GFP or 
MxCre;Ezh2+/Δ;GFP donor mice 5 wk after pIpC injection 
were mixed with 2.0 × 106 WT BM cells (1:100 ratio) and 
transplanted into lethally irradiated female recipients. For 
competitive transplantations at limiting dilution from Mx-
Cre;V617F;GFP or MxCre;V617F;Ezh2+/Δ;GFP donor mice, 
8,000 total BM cells were harvested 5 wk after pIpC injection 
and transplanted with 106 WT BM cells (1:250 ratio). Blood 
samples were taken every 6–8 wk to determine chimerism 
and for complete blood analysis. Secondary transplantations 
were performed with BM cells from primary recipients har-
vested at 30 wk after transplantation.
Purification of mouse LT-HSCs and MEP. Mouse LT-HSCs 
were purified from BM cells of SclCre mutant mice 12 wk 
after tamoxifen injection. BM mononuclear cells were stained 
with an allophycocyanin (APC)-conjugated anti–c-Kit anti-
bodies (BioLegend). c-Kit–positive cells were isolated with 
goat anti–APC microbeads (Miltenyi Biotec) through an LS 
column (Miltenyi Biotec). The c-Kit–positive cells were fur-
ther stained with antibody cocktail consisting of biotinylated 
anti–Gr-1, Mac-1, IL-7Rα, B220, CD4, CD8α, and Ter119 
monoclonal antibodies (lineage-marker cocktail), PE-conju-
gated anti-CD150, PE-Cy7–conjugated anti-CD48, and bril-
liant violet 421 (BV421)–conjugated anti–Sca-1 antibodies. 
Biotinylated antibodies were detected with streptavidin- 
APC-Cy7 (BioLegend). Mouse MEPs were also purified 
from spleen cells of SclCre mutant mice 12 wk after tamoxi-
fen injection. In brief, c-Kit–positive cells were isolated using 
PE-conjugated anti–c-Kit antibody and anti-PE microbeads 
with LS column (Miltenyi Biotec). The c-Kit–positive cells 
were further stained with lineage-marker cocktail followed 
by PE-Cy7–conjugated anti-CD16/32 (BioLegend), APC- 
conjugated anti-CD34 (BD), streptavidin-APC-Cy7, and 
BV421-conjugated anti–Sca-1 antibodies. Cell sorting was 
performed by Influx (BD), and results were analyzed with 
FlowJo software (Tree Star).
Transduction of mouse LT-HSCs and competitive repopula-
tion assays. Recombinant retrovirus vectors, MIGR1-IRES-
GFP, pMys-Hmga2-IRES-GFP, and pMys-Lin28b-IRES-GFP 
were provided by A. Iwama (Chiba University, Chuo-ku, 
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Chiba, Japan). LT-HSCs were sorted into 96-well microtiter 
plates coated with the recombinant fibronectin fragment 
CH-296 (RetroNectin; Takara Bio Inc.) at 300 cells/well and 
were incubated in StemSpan (STE MCE LL Technologies) 
supplemented with 100 ng/ml mouse SCF (PeproTech) and 
100 ng/ml human Tpo (PeproTech) for 24 h. The cells were 
transduced with a retrovirus vector at a multiplicity of infec-
tion of 800 in the presence of 10 µg/ml protamine sulfate 
(Sigma-Aldrich) and 1 µg/ml RetroNectin for 24  h. After 
transduction, cells were further incubated in in StemSpan 
supplemented with 10 ng/ml SCF and 10 ng/ml TPO. 150 
LT-HSCs transduced with the indicated retrovirus were trans-
planted intravenously into 8-wk-old female C57BL/6 mice 
irradiated at a dose of 9.5 Gy, together with 2.5 × 105 BM 
competitor cells from 8-wk-old C57BL/6 mice.
Peripheral blood analysis. Blood was collected from the tail 
vein or by cardiac puncture, and complete blood counts 
(CBCs) were determined on an Advia120 Hematology Ana-
lyzer using Multispecies version 5.9.0-MS software (Bayer).
Flow cytometry analysis. The whole blood was stained with 
APC-conjugated anti-Ter119 and PE-conjugated anti-CD61 
for erythrocyte and platelet analysis. White blood cells after 
RBC lyses were stained with PE-conjugated anti-CD8, PE-
Cy7–conjugated anti-B220, APC-conjugated anti–Mac-1, 
APC-Cy7–conjugated anti-CD4, and Pacific blue (PB)–con-
jugated anti-Gr1 (BioLegend). Single cell suspensions from 
BM and spleen were stained with lineage-marker cocktail 
followed by FITC-conjugated anti-CD41, PE-conjugated 
anti-CD150, PE-Cy7–conjugated anti-CD48, APC-conju-
gated anti–c-Kit, BV421-conjugated anti–Sca-1, and strepta-
vidin-APC-Cy7. For progenitor analysis, cells were stained 
with lineage-marker cocktail followed by FITC-conjugated 
anti-CD34 (BD), PE-conjugated anti-CD16/32, APC- 
conjugated anti–c-Kit, BV421-conjugated anti–Sca-1, and 
streptavidin-APC-Cy7 antibodies (BioLegend). For mega-
karyocytes and erythrocyte precursor analysis, cells were 
stained with FITC-conjugated anti-CD42c (Emfret), Dy-
light-647–conjugated anti-αIIbβ3 (CD41/61; Emfret), PE- 
conjugated anti-CD71, and APC-conjugated anti-Ter119. 
Analyses were performed on an LSRFortessa (BD) or CyAn 
ADP Analyzer (Beckman Coulter), and results were ana-
lyzed with FlowJo software.
Quantitative RT-PCR analysis. Total RNA was extracted from 
0.5 × 106 BM cells from SclCre mutant mice 12 wk after 
tamoxifen injection using TRIzol solution (Thermo Fisher 
Scientific) and reverse transcribed by High Capacity cDNA 
reverse transcription kit (Thermo Fisher Scientific) with 
an oligo dT primer. Real-time qPCR was performed with 
7500 Fast Real-Time PCR System (Thermo Fisher Scien-
tific), using the Power SYBR Green PCR Master mix and 
normalized with mouse Gusb. Sequences of primers are as 
follows: 5′-ACT TAC TGC TGG CAC CGT CT-3′ and 5′-
GTT GAA CAG AAA GCT GCA CA-3′ for mouse Ezh2 and 
5′-ATA AGA CGC ATC AGA AGC CG-3′ and 5′-ACT CCT 
CAC TGA ACA TGC GA-3′ for mouse Gusb. Total RNA 
from granulocytes of MPN patients were extracted and re-
verse transcribed using the same method (Lundberg et al., 
2014a). Real-time qPCR was performed with 7500 Fast 
Real-Time PCR System, using the TaqMan gene expression 
system (Thermo Fisher Scientific) and normalized by human 
GUSB. The collection of blood samples was performed at the 
study center in Basel, Switzerland approved by the local Eth-
ics Committee (Ethik Kommission Beider Basel) and at the 
study center in Florence, Italy according to a research pro-
tocol approved by local IRB in Florence (#2011/0014777 
and #2015/0015136). Written informed consent was ob-
tained from all patients in accordance with the Declaration 
of Helsinki. The diagnosis of MPN was established accord-
ing to the revised criteria of the World Health Organization 
(Vardiman et al., 2009).
Western blotting. Total BM cells (20 × 106) from SclCre mu-
tant mice 12 wk after tamoxifen injection were lysed and 
immediately boiled in 400 µl SDS sample buffer. The lysates 
were subjected to electrophoresis on NuPAGE 4–12% Bis-
Tris Protein Gels (Invitrogen) and transferred to nitrocellu-
lose membranes by Western blotting. The membranes were 
probed with antibodies against Ezh2 (CST), β-actin, histone 
H3 (Abcam), H3K27me27 (EMD Millipore), histone H2A 
(CST), and H2AK119Ub (CST). Signals were detected by 
HRP-conjugated anti–mouse IgG or HRP-conjugated anti–
rabbit IgG antibodies, followed by ECL detection.
ChIP assay. ChIP was performed using a True MicroChIP 
kit from Diagenode. In brief, 10,000 LSK cells or MEP cells 
isolated by FACS were cross-linked with 1% formaldehyde 
for 8 min at room temperature and incubated for 5 min after 
addition of 0.125 M glycine. Cells were washed with PBS 
and lysed by lysis buffer, and sonicated to the DNA fragments 
were 200–500 bp by Bioruptor Pico (Diagenode). Immuno-
precipitation was performed by using an anti-H3K27me27 
(EMD Millipore), and DNA was purified using MicroChIP 
DiaPure columns (Diagenode). qPCR analysis was per-
formed using Power SYBR Green PCR Master mix with 
7500 Fast Real-Time PCR System (Thermo Fisher Scien-
tific). Primer sequences are as follows: promoter region of 
Hmga2, 5′-CGA ATC GTG GAC AGG GAC TT-3′ and 5′-
GCC AAA GCG GCT GAC AAA-3′; promoter region of 
Lin28b, 5′-GGG AGA GAG GAG AGC GGA AG-3′ and 5′-
GGT GTG AAC CCG GAA GTA CAA-3′.
Next generation sequencing and bioinformatics analysis. 
Total RNA was isolated from 1,000 FACS-sorted LT-HSCs 
using Pico-Pure RNA isolation kit (ARC TUR US) or from 
230,000 FACS-sorted MEP cells using TRIzol-LS solution. 
Total RNA was quality-checked on the Bioanalyzer instru-
ment (Agilent Technologies) using the RNA 6000 Pico. 
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The library of LT-HSCs was prepared by using SMA RTer 
Low Input RNA kit with Low Input Library Prep kit (Ta-
kara Bio Inc.). The library of MEPs was prepared using by 
TruSeq Stranded mRNA Library Prep kit (Illumina). Sam-
ples were pooled to equal molarity and run on the Frag-
ment Analyzer for quality check and used for clustering on 
the NextSeq 500 instrument (Illumina). Samples were se-
quenced using the NextSeq 500 High Output kit 75-cycles 
(Illumina), and primary data analysis was performed with the 
Illumina RTA version 2.1.3 and bcl2fastq-2.16.0.10. Raw 
data were deposited in Gene Expression Omnibus under the 
accession no. GSE82074.
Reads were mapped against the mouse genome (ver-
sion mm9; NCBI build 37) using the spliced-read aligner 
STAR (Dobin et al., 2013). The mean faction of mapped 
reads was 80%. All subsequent gene expression data analysis 
was performed within the R software (R Foundation for 
Statistical Computing). Raw reads and mapping quality were 
assessed by the qQCReport function from the R/Biocon-
ductor software package QuasR (Gaidatzis et al., 2015). Ex-
pression of RefSeq genes was quantified by counting reads 
mapping into exons using the qCount function of QuasR. 
For gene expression visualization, the resulting count table 
was adjusted by library size and log transformed (log2 ex-
pression in figures). The full expression set was visualized as 
a heat map (unsupervised clustering of row and columns); 
it only includes genes that showed at least a 1.5 log2–fold 
change (relative to the mean) on an absolute scale in one of 
the samples and that were also significant (P ≤ 0.05) in one 
of the genotype comparisons. The heat map was generated 
using the NMF package (Gaujoux and Seoighe, 2010) with 
default clustering settings. For the PCA, genes were ordered 
by their absolute log2-fold change, and the top 1/4 (n = 
4708) were retained for the analysis. PCA was performed 
with the R function “prcomp.”
The R/Bioconductor software package edgeR (Mc-
Carthy et al., 2012) was used for detecting differentially 
expressed genes between genotypes. The model fitted by 
edgeR included both Ezh2 and Jak2 genotypes as well as 
their interaction effect and additionally adjusted for gender 
as a possible confounder. P-values for the contrasts between 
genotypes were calculated by likelihood ratio tests and ad-
justed for multiple testing by controlling the expected false 
discovery rate (Benjamini and Hochberg, 1995). Competitive 
gene set enrichment analysis was performed on all catego-
ries of the Molecular Signature Database (MSigDB) using 
the function CAM ERA of the edgeR package. The self-con-
tained gene set testing on gene signature of fetal liver HSCs 
(Copley et al., 2013) was conducted using the function ROA 
ST of the edgeR package.
Statistical analysis. Results are presented as means ± SEM. 
To assess the statistical significance among individual cohorts, 
one-way ANO VA with subsequent Bonferroni’s post-hoc 
multiple comparison test (Prism version 6 software; Graph-
Pad Software) or unpaired Student’s t test was used. P ≤ 0.05 
was considered significant.
Online supplemental material. Table S1, available as an Excel 
file, contains the complete gene list of differentially expressed 
transcripts found in LT-HSCs. Table S2, available as an Excel 
file, contains the complete gene list of differentially expressed 
transcripts found in MEP cells. Online supplemental 
material is available at http ://www .jem .org /cgi /content 
/full /jem .20151136 /DC1.
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